You are here

Clinical Trial To Evaluated Telcyta as Front-Line Treatment of Non-Small Cell Lung Cancer Initiated

PALO ALTO, Calif., March 9 /PRNewswire-FirstCall/ -- Telik, Inc. announced the initiation of a multicenter Phase 1-2a clinical trial in which TELCYTA™ (TLK286) will be evaluated in combination with cisplatin in the front-line treatment of Stage IIIb or IV non-small cell lung cancer (NSCLC). The trial is expected to enroll approximately 50 NSCLC patients who have not previously received chemotherapy. Platinum is the current mainstay of front-line metastatic lung cancer treatment.

The trial is based upon the clinical results reported at the AACR-NCI-EORTC meeting in November 2003 in which TELCYTA demonstrated the ability to contribute to platinum-based chemotherapy without unanticipated toxicities.

About Non-Small Cell Lung Cancer

Lung cancer is the leading cause of cancer deaths in men and women in the United States, according to the American Cancer Society (ACS). The ACS estimates that more than 173,000 new cases of lung cancer will be diagnosed in 2004 and an estimated 160,400 deaths will result from the disease, representing approximately 28% of all cancer deaths in the U.S.

About TELCYTA™ and TELCYTA™ Clinical Trials

A Phase 3 registration trial is ongoing using TELCYTA™ as a single agent in the treatment of ovarian cancer, and a Phase 3 registration trial is expected to begin in the near future in the treatment of NSCLC. For further information on TELCYTA™ trials, visit

TELCYTA™ is a small molecule tumor-activated drug which is activated by an enzyme present in higher levels in many human cancers than in normal tissues. Upon activation, an intracellular process known as apoptosis, or programmed cell death, is initiated. TELCYTA™, which has been evaluated in clinical trials in ovarian, NSCLC, breast and colorectal cancer, was discovered through the application of Telik's proprietary drug discovery technology, TRAP.

Source: Telik, Inc.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
National Statistics Report Factors In Race, Ethnicity for the First Time